Cambium Bio Ltd
Cambium Bio Limited, a clinical-stage regenerative medicine company, focuses on developing biologics for ophthalmology and tissue repair applications. The company provides lead product candidate is Elate Ocular for the treatment of dry eye disease. The company also develops Progenza, a stem cell platform for knee osteoarthritis and other tissue repair indications; and Sygenus, for wound healing i… Read more
Cambium Bio Ltd (CMB) - Total Assets
Latest total assets as of June 2025: AU$3.30 Million AUD
Based on the latest financial reports, Cambium Bio Ltd (CMB) holds total assets worth AU$3.30 Million AUD as of June 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Cambium Bio Ltd - Total Assets Trend (1999–2025)
This chart illustrates how Cambium Bio Ltd’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Cambium Bio Ltd - Asset Composition Analysis
Current Asset Composition (June 2025)
Cambium Bio Ltd's total assets of AU$3.30 Million consist of 14.2% current assets and 85.8% non-current assets.
| Asset Category | Amount (AUD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | AU$0.00 | 5.1% |
| Accounts Receivable | AU$275.72K | 8.4% |
| Inventory | AU$0.00 | 0.0% |
| Property, Plant & Equipment | AU$0.00 | 0.0% |
| Intangible Assets | AU$2.45 Million | 74.3% |
| Goodwill | AU$0.00 | 0.0% |
Asset Composition Trend (1999–2025)
This chart illustrates how Cambium Bio Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Cambium Bio Ltd's current assets represent 14.2% of total assets in 2025, a decrease from 21.0% in 1999.
- Cash Position: Cash and equivalents constituted 5.1% of total assets in 2025, down from 15.1% in 1999.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 74.0% of total assets, an increase from 0.0% in 1999.
- Asset Diversification: The largest asset category is intangible assets at 74.3% of total assets.
Cambium Bio Ltd Competitors by Total Assets
Key competitors of Cambium Bio Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Cambium Bio Ltd - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Cambium Bio Ltd generates 0.20x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Cambium Bio Ltd is currently not profitable relative to its asset base.
Cambium Bio Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.36 | 1.33 | 0.96 |
| Quick Ratio | 0.36 | 1.33 | 0.96 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | AU$-825.44K | AU$ 795.18K | AU$ -148.22K |
Cambium Bio Ltd - Advanced Valuation Insights
This section examines the relationship between Cambium Bio Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 7.13 |
| Latest Market Cap to Assets Ratio | 2.46 |
| Asset Growth Rate (YoY) | -41.7% |
| Total Assets | AU$3.30 Million |
| Market Capitalization | $8.11 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Cambium Bio Ltd's assets at a significant premium ( 2.46x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: Cambium Bio Ltd's assets decreased by 41.7% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Cambium Bio Ltd (1999–2025)
The table below shows the annual total assets of Cambium Bio Ltd from 1999 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-06-30 | AU$3.30 Million | -41.67% |
| 2024-06-30 | AU$5.65 Million | +127.41% |
| 2023-06-30 | AU$2.48 Million | -2.76% |
| 2022-06-30 | AU$2.55 Million | -69.98% |
| 2021-06-30 | AU$8.51 Million | +77.69% |
| 2020-06-30 | AU$4.79 Million | +88.43% |
| 2019-06-30 | AU$2.54 Million | -48.99% |
| 2018-06-30 | AU$4.98 Million | -45.63% |
| 2017-06-30 | AU$9.16 Million | +54.42% |
| 2016-06-30 | AU$5.93 Million | -38.05% |
| 2015-06-30 | AU$9.58 Million | -6.63% |
| 2014-06-30 | AU$10.26 Million | +154.98% |
| 2013-06-30 | AU$4.02 Million | +22.06% |
| 2012-06-30 | AU$3.30 Million | -21.71% |
| 2011-06-30 | AU$4.21 Million | +131.22% |
| 2010-06-30 | AU$1.82 Million | -96.37% |
| 2002-06-30 | AU$50.20 Million | -84.57% |
| 2001-06-30 | AU$325.41 Million | +12.46% |
| 2000-06-30 | AU$289.37 Million | +2.82% |
| 1999-06-30 | AU$281.42 Million | -- |